Acquired Haemophilia A. Which is the best therapeutic choice in older adults? Single center study of 4 cases

Submitted: 9 July 2017
Accepted: 17 May 2018
Published: 1 April 2019
Abstract Views: 1293
PDF: 952
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Acquired haemophilia A (AHA) is a rare bleeding disorder due to autoantibodies directed against coagulation factor VIII. The treatment is based on recombinant activated factor VII and activated prothrombin complex concentrate. However, mainly in older patients, severe thrombotic complications have been reported. Here we report the different therapeutic approaches in 4 cases of elderly patients with AHA and co-morbidities.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Mauro, E., Garlatti Costa, E., Zanier, A., Maset, M., Ermacora, A., Ghersetti, M., & Casarin, P. (2019). Acquired Haemophilia A. Which is the best therapeutic choice in older adults? Single center study of 4 cases. Reumatismo, 71(1), 37–41. https://doi.org/10.4081/reumatismo.2019.1041

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.